Back to results
US 11,634,731 B2Granted
Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing
AssigneeThe General Hospital Corporation
InventorsJ. Keith Joung, Jeffry D. Sander, Morgan Maeder, Yanfang Fu
Life of this patent
Estimating the term…
Abstract
Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems, using truncated guide RNAs (tru-gRNAs).
Claims19
A method of modifying a target region of a double-stranded DNA molecule in a cell, the method comprising expressing in or introducing into the cell:
- (a) a S. pyogenes CRISPR dCas9-heterologous functional domain fusion protein (dCas9-HFD) and
- (b) a guide RNA that includes a complementarity region at the 5′ end of the guide RNA consisting of 17-18 nucleotides that are complementary to 17-18 consecutive nucleotides of the complementary strand of a selected target sequence present on a double-stranded DNA molecule;
- wherein the target sequence is immediately 5′ of a protospacer adjacent motif (PAM);
- wherein the guide RNA is:
- (i) a single guide RNA that includes a complementarity region at the 5′ end of the single guide RNA consisting of 17-18 nucleotides that are complementary to 17-18 consecutive nucleotides of the complementary strand of a selected target genomic sequence on a double stranded DNA molecule, or
- (ii) a crRNA that includes at the 5′ end of the crRNA a complementarity region consisting of 17-18 nucleotides that are complementary to 17-18 consecutive nucleotides of the complementary strand of a selected target genomic sequence, and a tracrRNA;
- wherein the guide RNA complementarity region binds and directs the dCas9-HFD to the target region of the double-stranded DNA molecule, thereby modifying the target region of a double-stranded DNA molecule in a cell;
- and
- wherein the dCas9-HFD comprises a heterologous functional domain (HFD) that modifies gene expression, histones, or DNA.
6 more elements
Dependencies are inferred from the claim text.